Targets › BIRC5
4 programs from 4 companies in 8 trials: 4 Phase 2, 4 Phase 1; Oncology; next expected readout Dec 2026.
Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. (UniProt, O15392)
Open in Phaseline: the race on BIRC5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roswell Park Cancer Institute | SVN53-67/M57-KLH Peptide Vaccine Survivin peptide vaccine | BIRC5 | Phase 2 | Glioblastoma; Partial Response of Multiple Myeloma or Plasma Cell Leukemia | Dec 2026 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.) | DPX-Survivac Survivin-targeted immunogenic peptide vaccine | BIRC5 | Phase 2 | Ovarian Cancer; Relapsed Diffuse Large B-cell Lymphoma; Advanced Cancer; Breast Cancer | – |
| Children's Oncology Group | SurVaxM Survivin-based cancer vaccine | BIRC5 | Phase 1 | Medulloblastoma | Dec 2027 |
| Mustafa Khasraw, MBChB, MD, FRCP, FRACP | P30-EPS Vaccine Peptide-based tumor-associated antigen vaccine targeting EphA2, CMV pp65, and Survivin lin | EPHA2, BIRC5 | Phase 1 | Glioma, Malignant | Feb 2028 |
Ovarian Cancer (1) Relapsed Diffuse Large B-cell Lymphoma (1) Advanced Cancer (1) Breast Cancer (1) Glioblastoma (1) Partial Response of Multiple Myeloma or Plasma Cell Leukemia (1) Medulloblastoma (1) Glioma, Malignant (1)
mixed (3), protein or peptide (1)
ImmunoVaccine Technologies, Inc. (IMV Inc.) (1) Roswell Park Cancer Institute (1) Children's Oncology Group (1) Mustafa Khasraw, MBChB, MD, FRCP, FRACP (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.